Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1658-1667

  Oshita, Koichi ^a,b   Yamaoka, Kunihiro ^a   Udagawa, Nobuyuki ^c   Fukuyo, Shunsuke ^a   Sonomoto, Koshiro ^a   Maeshima, Keisuke ^a   Kurihara, Ryuji ^a   Nakano, Kazuhisa ^a   Saito, Kazuyoshi ^a   Okada, Yosuke ^a   Chiba, Kenji ^b   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c MATSUMOTO DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIBODY; BIOLOGICAL MARKER; CATHEPSIN K; OSTEOPROTEGERIN; PROTEIN NFATC1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ARTICLE; BONE DESTRUCTION; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN CELL; JOINT DESTRUCTION; LYMPHOCYTE; MESENCHYMAL STEM CELL; OSTEOCLAST; OSTEOCLASTOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; STAINING;

ACID PHOSPHATASE; CATHEPSIN K; CELL DIFFERENTIATION; CELL LINE; COCULTURE TECHNIQUES; HUMANS; ISOENZYMES; MESENCHYMAL STEM CELLS; MONOCYTES; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOPROTEGERIN; RHEUMATIC FEVER; RNA, SMALL INTERFERING;

EID: 79958062208     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30309     Document Type: Article

References (39)

1. Takayanagi H,. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009; 5: 667-76.
2. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 250-8. (Pubitemid 30395732)
3. Walsh N, Reinwald S, Manning C, Condon K, Iwata K, Burr D, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009; 24: 1572-85.
4. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol 2008; 18: 146-52.
5. Smolen J, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97. (Pubitemid 351392039)
6. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol 2008; 18: 447-54.
7. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7. (Pubitemid 29282067)
8. Aggarwal S, Pittenger MF,. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-22. (Pubitemid 40223708)
9. Klyushnenkova E, Mosca JD, Zernetkina V, Majumdar MK, Beggs KJ, Simonetti DW, et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 2005; 12: 47-57. (Pubitemid 40576763)
10. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-6. (Pubitemid 40656164)
11. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L,. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-33. (Pubitemid 351213419)
12. Rafei M, Campeau PA, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009; 182: 5994-6002.
13. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106: 1755-61. (Pubitemid 41208591)
14. Caplan A, Dennis J,. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-84. (Pubitemid 44128350)
15. Caplan A,. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217: 318-24.
16. LeBlanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al, Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-86. (Pubitemid 351626841)
17. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al, on behalf of the Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299-309. (Pubitemid 351705919)
18. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C,. Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009; 5: 392-9.
19. Planat-Benard V, Silvestre J, Cousin B, Andre M, Nibbelink M, Tamarat R, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004; 109: 656-63. (Pubitemid 38198874)
20. Noel D, Djouad F, Bouffi C, Mrugala D, Jorgensen C,. Multipotent mesenchymal stromal cells and immune tolerance. Leuk Lymphoma 2007; 48: 1283-9. (Pubitemid 47079355)
21. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G,. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007; 56: 1175-86. (Pubitemid 46608642)
22. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88-91.
23. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95. (Pubitemid 26026748)
24. De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006; 54: 3551-63. (Pubitemid 44737167)
25. 727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 2008; 149: 3688-97. (Pubitemid 351919592)
26. Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S,. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways. J Biol Chem 2008; 283: 11535-40.
27. 2 strongly inhibits human osteoclast formation. Endocrinology 2005; 146: 5204-14. (Pubitemid 41653034)
28. Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med 2009; 41: 315-24.
29. Park-Min K, Ji J, Antoniv T, Reid A, Silver R, Humphrey M, et al. IL-10 suppresses calcium-mediated costimulation of receptor activator NF-κB signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J Immunol 2009; 183: 2444-55.
30. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-34. (Pubitemid 46053063)
31. Udagawa N, Takahashi N, Yasuda H, Mizuno A, Itoh K, Ueno Y, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 2000; 141: 3478-84. (Pubitemid 32269038)
32. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12: 1260-8. (Pubitemid 28213402)
33. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-5. (Pubitemid 28418439)
34. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-74. (Pubitemid 30666247)
35. Romas E, Sims N, Hards D, Lindsay M, Quinn J, Ryan P, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002; 161: 1419-27.
36. Kong Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9. (Pubitemid 129516268)
37. + bone marrow hematopoietic progenitors. Endocrinology 1999; 140: 3736-43. (Pubitemid 30645430)
38. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou N,. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32: 1-7. (Pubitemid 36173806)
39. Fili S, Karalaki M, Schaller B,. Therapeutic implications of osteoprotegerin. Cancer Cell Int 2009; 9: 26.